Loading...
HSChapter 30
U.S. imports of immunological products in measured doses or for retail sale (HS 300215) totaled $5.6B in April 2026, traded with 41 countries.
Importers of Immunological Products in Measured Doses or for Retail Sale paid $29K in duties in April 2026 — an effective duty rate of 10% on $288K in dutiable value, based on actual customs collections rather than the published tariff schedule. Immunological Products in Measured Doses or for Retail Sale imports of $5.6B in April 2026 ran 29% above the year-to-date monthly average of $4.3B.
Last updated: April 2026 dataRetail-packaged and measured-dose immunological products — including monoclonal-antibody-based therapeutics — represent some of the highest-value pharmaceutical imports entering the US market. Germany and Ireland are the dominant suppliers, a pattern driven by the large number of FDA-approved biologics manufactured at European facilities. The US tariff schedule distinguishes monoclonal-antibody-containing products (3002150011) from other retail immunological preparations (3002150091 and 3002150100), and each line may carry different FDA review requirements at entry. Importers should verify that the foreign establishment is registered with FDA and that the specific product holds the appropriate approval or authorization before shipment.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
The HS structure separates retail/measured-dose presentations (heading 300215) from bulk non-retail forms (300214) because packaging and dosage form affect both the regulatory pathway and the commercial distribution channel. Measured-dose products are typically finished drug products subject to full FDA drug or biologics approval, while bulk forms may enter under different import authorization frameworks.
The importer must confirm the product has an active FDA Biologics License Application (BLA) or New Drug Application (NDA), that the foreign manufacturer is registered with FDA, and that the shipment is accompanied by a certificate of analysis and proper labeling. FDA may detain shipments that lack adequate documentation. Engaging a licensed customs broker with pharmaceutical experience is advisable given the complexity of admissibility review.
| Country | Imports | Exports | Balance |
|---|---|---|---|
| GERMANY | $2.2B | $104.4M | -$2.1B |
| IRELAND | $1.1B | $87.7M | -$984.2M |
| NETHERLANDS | $579.5M | $250.8M | -$328.7M |
| CHINA | $155.8M | $579.6M | +$423.8M |
| JAPAN | $511.3M | $122.9M | -$388.5M |
Supplier Network
Get discovered by U.S. importers searching for HS 300215 — Immunological Products in Measured Doses or for Retail Sale. Be the first supplier listed.
Monthly import values over time
HS10 import codes under this HS6 parent. Source: U.S. Harmonized Tariff Schedule.
| Code | Description | Import Value | Effective Tariff % | Duty Collected |
|---|---|---|---|---|
| 3002150011 | IMMUNOLOGICAL PRDCTS,CONTAIN MONOCLONAL ANTIBODIES | $5.1B | 9.96% | $8K |
| 3002150091 | IMMUNOLOGICAL PRODUCTS FOR RETAIL SALE, NESOI | $454.8M | 10.00% | $21K |
IMMUNOLOGICAL PRDCTS,CONTAIN MONOCLONAL ANTIBODIES
IMMUNOLOGICAL PRODUCTS FOR RETAIL SALE, NESOI
HS10 export codes under this HS6 parent. Source: U.S. Schedule B export classification.
| Code | Description | Export Value |
|---|---|---|
| 3002150100 | IMMUNOLOGICAL PRODUCTS,FOR RETAIL SALE | $2.1B |
IMMUNOLOGICAL PRODUCTS,FOR RETAIL SALE
645.1K kg
MEDICAMENTS NESOI, MEASURED DOSES, RETAIL PK NESOI
HS 300490
VACCINES FOR HUMAN MEDICINE
HS 300241
HORMONES ETC. (NO ANTIBIOTICS CONTAINED) DOSAGE FM
HS 300439
ANTISERA AND OTHER BLOOD FRACTIONS
HS 300212
IMMUNOLOGICAL PRODUCTS, MIXED, NOT IN MSRED DOSES
HS 300214
MEDICAMENTS CONT CORTEX HORMONES ETC DOSES
HS 300432
| State | Imports | Exports | Balance |
|---|---|---|---|
| North Carolina | $2.5B | $840.8M | -$1.6B |
| Pennsylvania | $776.2M | $170.0M | -$606.2M |
| Kentucky | $876.4M | $9.2M | -$867.3M |
| Port | Imports | Exports | Balance |
|---|---|---|---|
| ATLANTA, GA | $2.6B | $94.6M | -$2.5B |
| CHICAGO, IL | $949.8M | $365.3M | -$584.6M |
| NEW ORLEANS, LA | $683.2M | $51.1M | -$632.2M |